Therapeutic Class Overview
Antivirals, Influenza

INTRODUCTION

- Influenza is an infectious respiratory illness caused by the influenza A and influenza B viruses. Influenza epidemics occur annually in the United States, typically from late fall to early spring. Although the majority of infected individuals recover without complications, some cases of influenza result in severe illness or death (Grohskopf et al 2018).
- The virus is primarily transmitted through direct contact with large-particle respiratory droplets from an infected individual's coughs and sneezes. It is also spread through contact with surfaces contaminated by infected respiratory droplets. Adults begin to shed virus 1 day prior to symptom onset, and they remain contagious for 5 to 7 days after falling ill (Centers for Disease Control and Prevention [CDC] 2016).
- Signs and symptoms of uncomplicated influenza illness include fever, myalgia, headache, malaise, nonproductive cough, sore throat, and rhinitis. Complications of influenza infection include sinusitis, otitis media, pneumonia, sepsis, and exacerbation of chronic medical conditions. Elderly adults, young children, pregnant women, and patients with chronic medical conditions have a higher risk of developing complications from influenza (CDC 2018[a]).
- Annual influenza vaccination is the most effective method for preventing seasonal influenza virus infection and its complications. Antiviral prescription medications are also available for influenza prophylaxis and treatment; however, antiviral chemoprophylaxis is not a substitute for annual influenza vaccination (Grohskopf et al 2018).
- Initiation of antiviral therapy to treat influenza is recommended as early as possible for patients with confirmed or suspected influenza who are hospitalized; have severe, complicated, or progressive illness; or are at higher risk for influenza complications (Fiore et al 2011).
- Three classes of antiviral medications are available and included in this review. The adamantanes include amantadine and Flumadine (rimantadine). The neuraminidase inhibitors include Rapivab (peramivir), Relenza (zanamivir), and Tamiflu (oseltamivir). Currently, the only endonuclease inhibitor on the market is Xofluza (baloxavir marboxil), which was approved by the Food and Drug Administration (FDA) in late October 2018.
- Resistance to adamantanes is high (> 99%) among currently circulating influenza A virus strains, and these agents lack activity against influenza B virus. Therefore, amantadine and rimantadine are not recommended for treatment or chemoprophylaxis during the current influenza season (CDC 2018[b]).
- The neuraminidase inhibitors and baloxavir marboxil are active against both influenza A and influenza B viruses. Peramivir, zanamivir, oseltamivir, and baloxavir marboxil are the only antivirals recommended for the current influenza season in the United States (CDC 2018[b]).
- Circulating influenza viruses may evolve, and drug-resistant influenza virus strains have been reported. Prescribers should refer to influenza drug susceptibility patterns when selecting an antiviral agent (CDC 2018[b]).
- Medispan class: Antiparkinson, Dopaminergic and Influenza Agents. The only agent from the Antiparkinson, Dopaminergic category that will be included in this review is amantadine for the influenza indication.

Table 1. Medications Included Within Class Review

<table>
<thead>
<tr>
<th>Drug</th>
<th>Generic Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>amantadine</td>
<td>✓</td>
</tr>
<tr>
<td>Flumadine (rimantadine)</td>
<td>✓</td>
</tr>
<tr>
<td>Rapivab (peramivir)</td>
<td>-</td>
</tr>
<tr>
<td>Relenza (zanamivir)</td>
<td>-</td>
</tr>
<tr>
<td>Tamiflu (oseltamivir)</td>
<td>✓</td>
</tr>
<tr>
<td>Xofluza (baloxavir marboxil)</td>
<td>-</td>
</tr>
</tbody>
</table>

(Drugs@FDA 2018, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2018)
### INDICATIONS

**Table 2. Food and Drug Administration Approved Indications**

<table>
<thead>
<tr>
<th>Indication</th>
<th>amantadine&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Flumadine (rimantadine)</th>
<th>Rapivab&lt;sup&gt;3&lt;/sup&gt; (peramivir)</th>
<th>Relenza&lt;sup&gt;4&lt;/sup&gt; (zanamivir)</th>
<th>Tamiflu&lt;sup&gt;5&lt;/sup&gt; (oseltamivir)</th>
<th>Xofluza (baloxavir marboxil)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older)</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prophylaxis against influenza A virus in children (1 to 16 years of age)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than 2 days</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prophylaxis of influenza in adults and pediatric patients aged 5 years and older</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis of influenza A and B in patients 1 year and older</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Indication</td>
<td>amantadine</td>
<td>Flumadine (rimantadine)</td>
<td>Rapivab (peramivir)</td>
<td>Relenza (zanamivir)</td>
<td>Tamiflu (oseltamivir)</td>
<td>Xofluza (baloxavir marboxil)</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>------------------------</td>
<td>--------------------</td>
<td>--------------------</td>
<td>----------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Treatment of acute uncomplicated influenza in patients 12 years and older who have been symptomatic for no more than 48 hours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
</tr>
</tbody>
</table>

1 The changing of viruses over time is a limitation of use for antivirals. The emergence of resistance mutations could decrease drug effectiveness. Other factors, such as changes in viral virulence, may also diminish the clinical benefit of antivirals. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when selecting an antiviral.

2 Amantadine is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

3 Limitations of use for peramivir:
   - Efficacy is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus; a limited number of subjects infected with influenza B virus were enrolled.
   - Efficacy could not be established in patients with serious influenza requiring hospitalization.

4 Limitations of use for zanamivir:
   - Not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to the risk of serious bronchospasm.
   - Has not been proven effective for treatment of influenza in individuals with underlying airways disease.
   - Has not been proven effective for prophylaxis of influenza in the nursing home setting.

5 Limitations of use for oseltamivir:
   - Not recommended for patients with end-stage renal disease not undergoing dialysis.


Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

**CLINICAL EFFICACY SUMMARY**

**Adamantanes**
- One systematic review assessed the efficacy and safety of adamantanes in healthy adults by analyzing 20 prophylaxis and 13 treatment randomized trials comparing amantadine or rimantadine with placebo. For prophylaxis, amantadine was 61% better than placebo at reducing influenza risk (p < 0.001). Although rimantadine was 72% better than placebo at preventing influenza, statistical significance was not achieved. There was significant heterogeneity between the prophylaxis trials, and only a small sample size was available for rimantadine compared to amantadine. For treatment, amantadine and rimantadine both reduced the duration of fever by 1 day. Both agents caused gastrointestinal side effects, but amantadine caused significantly more adverse effects in the central nervous system than rimantadine (Jefferson et al 2006[a]).
- The adamantanes are not currently recommended for treatment of influenza due to high levels of resistance in influenza A viruses and lack of efficacy against influenza B viruses (CDC 2018[b], Uyeki et al 2018).

**Neuraminidase inhibitors**

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
• One systematic review analyzed 20 oseltamivir and 26 zanamivir randomized, placebo-controlled trials in order to better define their efficacy and safety. In prophylaxis trials, the risk of symptomatic influenza was reduced by 3.05% in patients treated with oseltamivir compared to placebo. In adults, the time to first alleviation of symptoms was reduced by 0.7 days (p < 0.0001) in patients receiving oseltamivir compared to placebo and 0.6 days (p < 0.00001) in patients receiving zanamivir compared to placebo. Oseltamivir significantly reduced the time to alleviation of symptoms in non-asthmatic children and decreased the incidence of self-reported pneumonia. Zanamivir significantly reduced the risk of bronchitis in adults with influenza. Neither treatment was a significant improvement over placebo in time to symptom alleviation in asthmatic children or risk of hospitalizations, otitis media, or sinusitis. Many studies included were at a high risk of selection bias due to inadequate reporting and a high risk of attrition bias due to selective reporting. All trials were sponsored by the manufacturers (Jefferson et al 2014).

• In a systematic review of other published systematic reviews and meta-analyses, treatment of influenza with neuraminidase inhibitors (oseltamivir or zanamivir) was found to be likely effective in reducing mortality among hospitalized patients; the odds of mortality appeared especially lower when therapy was started early (≤ 48 hours of symptom onset). When used for treatment in the general population, these agents appear to reduce the duration of symptoms by approximately 0.5 to 1 day. Both oseltamivir and zanamivir were found likely to be effective at reducing secondary symptomatic influenza transmission when used prophylactically (Doll et al 2017).

• Peramivir intravenous (IV) infusion is approved for the treatment of influenza A and B in adults. The primary endpoint for the main clinical trial supporting FDA approval of peramivir was time to alleviation of symptoms. The trial evaluated 296 previously healthy adults presenting with the onset of influenza-like illness within the previous 48 hours and a positive influenza rapid antigen test. In this multicenter, double-blind, placebo-controlled clinical trial, patients were randomized to peramivir 300 mg, 600 mg, or placebo as a single IV dose. Acetaminophen use was permitted. Patients self-reported body temperature, symptoms, and resumption of activities over 14 days. The primary endpoint, the median time to alleviation of symptoms, was significantly earlier with peramivir 300 mg (59.1 hours) and 600 mg (59.9 hours) compared to placebo (81.8 hours; both p = 0.0092). There was no significant difference in the incidence of all adverse events in patients receiving peramivir compared to placebo. Diarrhea was the most common adverse event, occurring in 14.1%, 15.2% and 17% of the peramivir 300 mg, 600 mg, and placebo groups, respectively (Kohno et al 2010).

• Although studies have evaluated peramivir in hospitalized patients and in children, both of these populations are not included in the FDA-approved labeling (De Jong et al 2014, Ison et al 2014, Ison et al 2013, Sugaya et al 2012). The Phase 3 clinical trial of peramivir in hospitalized influenza patients failed to meet its primary endpoint of reducing the time to clinical resolution compared to placebo. There are no clinical endpoints that have been validated for clinical trials of neuraminidase inhibitors treating hospitalized patients with influenza (FDA 2014). In 2009, the United States issued an Emergency Use Authorization (EUA) program allowing peramivir for the treatment of suspected or confirmed 2009 H1N1 influenza A virus infection in hospitalized patients (Birmkrant 2009). Patients eligible for treatment were hospitalized, unable to tolerate or unresponsive to other available antivirals, or lacked a dependable oral or inhalation drug delivery route. The Public Health Emergency determination for the 2009 H1N1 influenza pandemic expired on June 23, 2010 (CDC 2010).

• Numerous placebo-controlled trials have demonstrated the efficacy of neuraminidase inhibitors individually, but head-to-head trials directly comparing the agents are limited. One randomized, double-blind, placebo-controlled safety trial compared the use of oseltamivir, zanamivir and placebo in 390 healthy adults for influenza chemoprophylaxis over 16 weeks. The study showed that both treatments were well tolerated compared to placebo, and there were no discontinuations due to adverse events (Anekthananon et al 2013).

• A Phase 3, multinational, multicenter, double-blind, randomized, noninferiority trial compared a single dose of 300 or 600 mg IV peramivir to 5 days of oral oseltamivir in 1,091 patients with seasonal influenza. The primary endpoint, time to alleviation of influenza symptoms, had a median of 78.0 hours in patients receiving 300 mg of peramivir, 81.0 hours in patients receiving 600 mg of peramivir, and 81.8 hours in patients receiving oseltamivir. Both strengths of peramivir were noninferior to oseltamivir with a noninferiority margin of 0.170. There was no significant difference between treatments in the incidence of complications of influenza infection (Kohno et al 2011).

• A meta-analysis including 2 controlled clinical trials and 5 observational trials (N = 1676) examined the comparative efficacy of IV peramivir and oral oseltamivir in the treatment of seasonal influenza. No significant differences between treatments were noted for the following outcomes: mortality, hospital length of stay, virus titer 48 hours after admission, and incidence of adverse events. However, the time to resolution of influenza symptoms or fever was shorter with peramivir than with oseltamivir treatment (mean difference, -7.17 hours; p < 0.01) (Lee et al 2017).
• Observational studies comparing the clinical efficacy of peramivir, zanamivir, and oseltamivir in treating influenza have demonstrated within-class variation in the time to alleviation of influenza symptoms. The lack of robust data from randomized, head-to-head trials prevents the recommendation of one neuraminidase inhibitor over another. Local and seasonal susceptibility trends, route of administration, and patient-specific factors such as age and compliance should be taken into account when selecting an agent for antiviral drug therapy (Kawai et al 2008, Takemoto et al 2013).
• While influenza virus strains resistant to specific neuraminidase inhibitors have emerged, overall resistance remains low. According to surveillance data on seasonal influenza virus strains, the rate of resistance to oseltamivir is 1 to 3% and resistance to zanamivir is < 1% (Li et al 2015).

Endonuclease inhibitor
• In a Phase 3, double-blind, randomized, placebo- and oseltamivir-controlled trial (CAPSTONE-1), 1436 patients 12 to 64 years of age with influenza-like illness were randomized in a 2:2:1 ratio to receive a single, weight-based oral dose of baloxavir marboxil, treatment-dose oseltamivir for 5 days, or matching placebo. The primary endpoint, time to alleviation of influenza symptoms, was 53.7 hours (95% confidence interval [CI], 49.5 to 58.5) with baloxavir marboxil compared with 80.2 hours (95% CI, 72.6 to 87.1) with placebo (p < 0.001). The median time to alleviation of symptoms was similar between baloxavir marboxil and oseltamivir (53.5 hours and 53.8 hours, respectively). Treatment-related adverse events were more common with oseltamivir (8.4%) than baloxavir marboxil (4.4%; p = 0.009), or placebo (3.9%) (Hayden et al 2018).

CLINICAL GUIDELINES
• Annual influenza vaccination is the most effective method for preventing seasonal influenza virus infection and its complications. All individuals 6 months of age and older should receive an influenza vaccination each year, unless contraindicated. Prophylactic antiviral administration is not a substitute for early influenza vaccination (Grohskopf et al 2018).
• Key recommendations from the CDC include the following (CDC 2018[b]):
  o Widespread or routine use of antiviral medications for prophylaxis is not recommended except as one of multiple interventions to control institutional influenza outbreaks. Routine use of post-exposure chemoprophylaxis is not recommended, but may be considered in certain patients who are either not candidates for vaccination or received their annual vaccination less than 2 weeks prior to exposure. Oseltamivir and zanamivir are agents recommended for chemoprophylaxis.
  o The antivirals recommended for influenza treatment in the current influenza season include oseltamivir, zanamivir, peramivir, and baloxavir marboxil. Treatment of influenza with antiviral therapy is recommended as early as possible for patients with confirmed or suspected influenza who are hospitalized; have severe, complicated, or progressive illness; or are at a high risk for complications.
  o Populations at a high risk for influenza complications and recommended to receive antiviral treatment include children younger than 2 years old, adults age 65 and above, pregnant or postpartum women, American Indians, Alaska Natives, obese patients with a body mass index (BMI) of 40 kg/m² and above, patients younger than 19 years old receiving long-term treatment with aspirin, residents of nursing homes, and patients with immunosuppression, chronic disorders (eg, pulmonary, cardiovascular, renal, hepatic, hematological and metabolic), or neurologic conditions.
  o Early antiviral treatment can shorten the duration of fever and illness symptoms, and may reduce the risk of influenza-related complications such as otitis media, pneumonia, and respiratory failure. In observational studies, early treatment with oseltamivir has been reported to reduce deaths in hospitalized adults and shorten the duration of hospitalization in children. Clinical benefit is greatest when antiviral treatment is administered early, especially within 48 hours of influenza illness onset.
  o Key recommendations from the Infectious Diseases Society of America include the following (Uyeki et al 2018):
    o Clinicians should start antiviral treatment as soon as possible for adults and children with documented or suspected influenza who are hospitalized, have severe or progressive illness, or are at high risk of complications; children < 2 years and adults ≥ 65 years of age; and women who are pregnant or within 2 weeks postpartum.
Clinicians can consider antiviral treatment for patients with documented or suspected influenza who are not at high risk of complications if they are outpatients with illness onset ≤ 2 days before presentation, or symptomatic outpatients who are household contacts or healthcare providers of persons at high risk of developing complications.

A single neuraminidase inhibitor (oseltamivir, zanamivir, or peramivir) is recommended for treatment; combination neuraminidase inhibitors are not recommended.

Antiviral drugs should not be used for routine or widespread chemoprophylaxis outside of institutional outbreaks. Antiviral chemoprophylaxis with oral oseltamivir or inhaled zanamivir can be considered for individuals in certain situations, eg, those at high risk for complications who are not eligible for vaccination or for whom the vaccine is expected to have low effectiveness, and those in close contact with individuals at high risk of complications who are not eligible for vaccination or chemoprophylaxis.

SAFETY SUMMARY

- Common adverse events with adamantanes include nausea, dizziness, insomnia, headache, anorexia, dry mouth, and agitation.
- Amantadine and rimantadine should be used with caution in patients with epilepsy due to an increased risk for seizures.
- Amantadine has anticholinergic effects and is contraindicated in patients with untreated angle closure glaucoma. There have also been reports of death from overdose and suicide attempts with amantadine.
- Common adverse events with neuraminidase inhibitors include nausea, vomiting, and headache. The most common adverse effect with peramivir is diarrhea.
- All 3 neuraminidase inhibitors have labeled warnings for neuropsychiatric events such as hallucinations and delirium. Patients should be monitored for signs of abnormal behavior.
- Oseltamivir and peramivir have warnings for serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome.
- Zanamivir has a warning for bronchospasm and should not be used in patients with asthma or chronic obstructive pulmonary disease. It is also contraindicated in patients with milk protein allergies.
- Common adverse events with baloxavir marboxil include diarrhea, headache, bronchitis, nausea, and nasopharyngitis.

DOSING AND ADMINISTRATION

Table 3. Dosing and Administration*

<table>
<thead>
<tr>
<th>Drug</th>
<th>Available Formulations</th>
<th>Route</th>
<th>Usual Recommended Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>amantadine</td>
<td>Capsules, oral solution, tablets</td>
<td>Oral</td>
<td>Once daily or twice daily</td>
<td>Should be taken for 10 days following a known exposure.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adults: 200 mg once daily or 100 mg twice daily</td>
<td>If using in conjunction with vaccine until antibody response, take for 2 to 4 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pediatric patients: 1 to 9 years: 4.4 to 8.8 mg/kg/day not to exceed 150 mg per day</td>
<td>Treatment of illness should be started within 24 to 48 hours of symptom onset and continued for 24 to 48 hours after symptoms disappear.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>9 to 12 years: 100 mg twice daily</td>
<td>For adult patients intolerant to 200 mg daily dose because of central nervous system or other toxicities: 100 mg daily dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The safety and efficacy of amantadine in newborn infants and infants below the age of 1 year have not been established.</td>
<td>Because amantadine is primarily excreted in the urine, it accumulates when renal function declines. Thus, the dose of amantadine should be reduced in patients with renal impairment and in individuals</td>
</tr>
</tbody>
</table>

Data as of December 27, 2018 JZ-U/CK-U/AKS

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
<table>
<thead>
<tr>
<th><strong>Flumadine (rimantadine)</strong></th>
<th><strong>Tablets</strong></th>
<th><strong>Oral</strong></th>
<th>Twice daily</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adults (17 years and older)</strong></td>
<td>100 mg twice daily for 7 days</td>
<td><strong>Prophylaxis:</strong></td>
<td>100 mg twice daily</td>
</tr>
<tr>
<td><strong>Pediatric patients</strong></td>
<td><strong>Prophylaxis in patients 1 to 9 years:</strong> 5 mg/kg/day, not to exceed 150 mg per day</td>
<td><strong>Pediatric patients</strong></td>
<td><strong>Prophylaxis in patients 1 to 9 years:</strong> 5 mg/kg/day, not to exceed 150 mg per day</td>
</tr>
<tr>
<td>10 to 16 years: Refer to the adult dose</td>
<td></td>
<td>10 to 16 years: Refer to the adult dose</td>
<td>10 to 16 years: Refer to the adult dose</td>
</tr>
<tr>
<td>The safety and efficacy of rimantadine in pediatric patients below the age of 1 year have not been established.</td>
<td></td>
<td>The safety and efficacy of rimantadine in pediatric patients below the age of 1 year have not been established.</td>
<td>The safety and efficacy of rimantadine in pediatric patients below the age of 1 year have not been established.</td>
</tr>
</tbody>
</table>

Who are 65 years of age or older according to the following:

- **For CrCl = 30 to 50 mL/min:**
  200 mg 1st day, then 100 mg daily
- **For CrCl = 15 to 29 mL/min:**
  200 mg 1st day, then 100 mg on alternate days
- **For CrCl < 15 mL/min and HD:** 200 mg every 7 days
- **For patients ≥ 65 years:**
  100 mg once daily

The dose of amantadine may need reduction in patients with congestive heart failure, peripheral edema, or orthostatic hypotension.

---

<table>
<thead>
<tr>
<th><strong>Rapivab (peramivir)</strong></th>
<th><strong>Injection</strong></th>
<th><strong>IV</strong></th>
<th>Patients ≥ 13 years: 600 mg as a single dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients &lt; 13 years: 2 to 12 years: 12 mg/kg (maximum dose 600 mg) as a single dose</td>
<td><strong>Safety and effectiveness in</strong></td>
<td><strong>One time dose should be provided within 2 days of onset of influenza symptoms</strong></td>
<td><strong>One time dose should be provided within 2 days of onset of influenza symptoms</strong></td>
</tr>
</tbody>
</table>

A single dose administered by IV infusion for a minimum of 15 minutes.

Peramivir must be diluted prior to administration.

---

Data as of December 27, 2018 JZ-U/CK-U/AKS

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
<table>
<thead>
<tr>
<th>Drug (Brand)</th>
<th>Formulation</th>
<th>Administration</th>
<th>Frequency</th>
<th>Dosage Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relenza (zanamivir)</td>
<td>Inhalation powder (in blisters)</td>
<td>Oral inhalation via Diskhaler device</td>
<td>Once daily or twice daily, depending on the indication</td>
<td>Dose adjustment in adults and adolescents 13 years of age or older with CrCl = 30 to 49 mL/min: 200 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dose adjustment in pediatric patients 2 to 12 years of age with CrCl = 30 to 49 mL/min: 4 mg/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dose adjustment in adults and adolescents 13 years of age or older with CrCl = 10 to 29 mL/min: 100 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dose adjustment in pediatric patients 2 to 12 years of age with CrCl = 10 to 29 mL/min: 2 mg/kg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HD: Administer after dialysis</td>
</tr>
<tr>
<td>Tamiflu (oseltamivir)</td>
<td>Capsules, powder for oral suspension</td>
<td>Oral</td>
<td>Once daily or twice daily, depending on the indication</td>
<td>The 10 mg dose is provided by 2 inhalations (one 5 mg blister per inhalation).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Patients scheduled to use an inhaled bronchodilator at the same time as zanamivir should use their bronchodilator before taking zanamivir.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If zanamivir is prescribed for children, it should be used only under adult supervision and instruction, and the supervising adult should first be instructed by a healthcare professional.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Due to the low systemic bioavailability of zanamivir following oral inhalation, no dosage adjustments are necessary for patients with renal impairment; however, the potential for drug accumulation should be considered.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Start treatment within 48 hours of symptom onset or close contact with the infected individual.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Taking with food may enhance tolerability. In an emergency, a suspension can be made from capsules.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dosage adjustment is recommended for patients with a CrCl between 10 and 60 mL/minute and for patients with ESRD undergoing routine HD or CAPD.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Not recommended for patients with ESRD not undergoing dialysis.</td>
</tr>
<tr>
<td>Xofluza (baloxavir marboxil)</td>
<td>Tablets</td>
<td>Oral</td>
<td>Single, weight-based dose</td>
<td>No dosage adjustment for mild to moderate hepatic impairment. Safety not evaluated in patients with severe hepatic impairment.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Patients &lt; 13 years</strong>&lt;br&gt;<strong>Treatment:</strong>&lt;br&gt;· 2 weeks to &lt; 1 year: 3 mg/kg twice daily for 5 days&lt;br&gt;· 1 to 12 years: 30 to 75 mg twice daily for 5 days; specific weight-based dosing recommendations as follows:&lt;br&gt;  ○ ≤ 15 kg: 30 mg twice daily&lt;br&gt;  ○ 15.1 kg to 23 kg: 45 mg twice daily&lt;br&gt;  ○ 23.1 kg to 40 kg: 60 mg twice daily&lt;br&gt;  ○ ≥ 40.1 kg: 75 mg twice daily&lt;br&gt;<strong>Prophylaxis:</strong>&lt;br&gt;· 1 to 12 years: 30 to 75 mg once daily for 10 days; specific weight-based dosing recommendations as follows:&lt;br&gt;  ○ ≤ 15 kg: 30 mg once daily&lt;br&gt;  ○ 15.1 kg to 23 kg: 45 mg once daily&lt;br&gt;  ○ 23.1 kg to 40 kg: 60 mg once daily&lt;br&gt;  ○ ≥ 40.1 kg: 75 mg once daily&lt;br&gt;· During a community outbreak, can continue for up to 6 weeks (or up to 12 weeks in immunocompromised patients).</td>
<td>Initiate treatment within 48 hours of symptom onset.&lt;br&gt;Take orally as a single dose with or without food; however, coadministration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements should be avoided.&lt;br&gt;No dosage adjustment is recommended for CrCl ≥ 50 mL/min or mild to moderate impairment.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CAPD = continuous ambulatory peritoneal dialysis; CrCl = creatinine clearance; ESRD = end stage renal disease; HD = hemodialysis

*See the current prescribing information for full details

**CONCLUSION**

- The first line of protection against influenza is vaccination. All individuals 6 months of age and older without contraindications should receive yearly influenza vaccination (AAP 2018, Fiore et al 2011, Grohskopf et al 2018).
- Antivirals are available for the prevention and treatment of influenza. Overall, the adamantanes, the neuraminidase inhibitors, and baloxavir marboxil (an endonuclease inhibitor) have demonstrated safety and efficacy for their respective indications. However, amantadine and rimantadine are not currently recommended due to high rates of resistance in circulating influenza virus strains (CDC 2018[b]).
- Zanamivir and oseltamivir are both effective in preventing influenza and are recommended in certain situations for chemoprophylaxis, but are not substitutes for annual vaccination (CDC 2018[b], Uyeki et al 2018). Peramivir and baloxavir marboxil are not approved or recommended for influenza prophylaxis (CDC 2018[b]).
- Peramivir, zanamivir, oseltamivir, and baloxavir marboxil effectively treat influenza by reducing the duration of fever and illness. Initiation of treatment is recommended as soon as possible for patients with suspected influenza who are hospitalized, severely ill, or at high risk for influenza complications (CDC 2018[b]).
- Limited within-class comparisons prevent the recommendation of one neuraminidase inhibitor over another. Factors to consider when selecting an antiviral agent include the route of administration, seasonal and geographical susceptibility trends, and patient-specific factors such as age and compliance (Takemoto et al 2013).
- The most common adverse events with amantadine and rimantadine are nausea, insomnia, dizziness, headache, anorexia, dry mouth, and agitation. The adamantanes are associated with an increased risk for seizures.
- The most common adverse events with zanamivir and oseltamivir are headache, nausea, and vomiting. Diarrhea is the most common adverse event with peramivir. The neuraminidase inhibitors have a labeled warning for neuropsychiatric events such as delirium and abnormal behavior leading to injury.
- The most common adverse events with baloxavir marboxil are diarrhea, headache, bronchitis, nausea, and nasopharyngitis.

**REFERENCES**

- Amantadine tablets [package insert], Sunrise, FL: Cipla USA, Inc.; May 2017.


Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929-44.


Publication Date: December 28, 2018